Equities

Anavex Life Sciences Corp

Anavex Life Sciences Corp

Actions
  • Price (EUR)8.59
  • Today's Change-0.002 / -0.02%
  • Shares traded50.00
  • 1 Year change+58.96%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments151149152
Total Receivables, Net2.713.199.14
Total Inventory------
Prepaid expenses0.650.350.36
Other current assets, total----0.02
Total current assets154153162
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets154153162
LIABILITIES
Accounts payable4.323.824.74
Accrued expenses7.305.945.61
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.920.440.44
Total current liabilities131011
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities131011
SHAREHOLDERS EQUITY
Common stock0.080.080.08
Additional paid-in capital435388348
Retained earnings (accumulated deficit)(293)(246)(198)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity142142151
Total liabilities & shareholders' equity154153162
Total common shares outstanding827876
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.